📣 VC round data is live. Check it out!

Cytek Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cytek Biosciences and similar public comparables like IBA Group, Sofwave Medical, Beta Bionics, Wellgistics Health and more.

Cytek Biosciences Overview

About Cytek Biosciences

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.


Founded

2014

HQ

United States

Employees

648

Financials (LTM)

Revenue: $204M
EBITDA: ($2M)

EV

$282M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cytek Biosciences Financials

Cytek Biosciences reported last 12-month revenue of $204M and negative EBITDA of ($2M).

In the same LTM period, Cytek Biosciences generated $105M in gross profit, ($2M) in EBITDA losses, and had net loss of ($52M).

Revenue (LTM)


Cytek Biosciences P&L

In the most recent fiscal year, Cytek Biosciences reported revenue of $201M and EBITDA of ($663K).

Cytek Biosciences is unprofitable as of last fiscal year, with gross margin of 52%, EBITDA margin of (0%), and net margin of (33%).

See analyst estimates for Cytek Biosciences
LTMLast FY202320242025202620272028
Revenue$204M$201M$193M$200M$201M
Gross Profit$105M$104M$109M$111M$104M
Gross Margin51%52%57%55%52%
EBITDA($2M)($663K)($4M)($10M)($17M)
EBITDA Margin(1%)(0%)(2%)(5%)(9%)
EBIT Margin(14%)(13%)(14%)(10%)(20%)
Net Profit($52M)($67M)($12M)($6M)($67M)
Net Margin(25%)(33%)(6%)(3%)(33%)

Financial data powered by Morningstar, Inc.

Cytek Biosciences Stock Performance

Cytek Biosciences has current market cap of $517M, and enterprise value of $282M.

Market Cap Evolution


Cytek Biosciences' stock price is $4.00.

Cytek Biosciences share price decreased by 12.0% in the last 30 days, and increased by 44.6% in the last year.

Cytek Biosciences has an EPS (earnings per share) of $-0.52.

See more trading valuation data for Cytek Biosciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$282M$517M0.0%-12.0%-10.6%44.6%$-0.52

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cytek Biosciences Valuation Multiples

Cytek Biosciences trades at 1.4x EV/Revenue multiple, and (176.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for Cytek Biosciences

EV / Revenue (LTM)


Cytek Biosciences Financial Valuation Multiples

As of May 26, 2026, Cytek Biosciences has market cap of $517M and EV of $282M.

Cytek Biosciences has a P/E ratio of (10.0x).

LTMLast FY202320242025202620272028
EV/Revenue1.4x1.4x1.5x1.4x1.4x
EV/EBITDA(176.7x)n/m(64.1x)(28.2x)(16.2x)
EV/EBIT(10.2x)(10.4x)(10.1x)(13.8x)(7.0x)
EV/Gross Profit2.7x2.7x2.6x2.5x2.7x
P/E(10.0x)(7.8x)(42.6x)(85.9x)(7.8x)
EV/FCF(31.8x)n/m13.0x(31.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cytek Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cytek Biosciences Margins & Growth Rates

Cytek Biosciences grew revenue by 4% and EBITDA by 353% in the last fiscal year.

In the most recent fiscal year, Cytek Biosciences reported gross margin of 52%, EBITDA margin of (0%), and net margin of (33%).

See estimated margins and future growth rates for Cytek Biosciences

Cytek Biosciences Margins

Last FY202420252026202720282029
Gross Margin52%55%52%51%
EBITDA Margin(0%)(5%)(9%)(1%)
EBIT Margin(13%)(10%)(20%)(14%)
Net Margin(33%)(3%)(33%)(14%)
FCF Margin(4%)11%(4%)

Cytek Biosciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth4%4%1%4%
Gross Profit Growth1%2%(6%)1%
EBITDA Growth353%128%73%(83%)
EBIT Growth5%(26%)97%(29%)
Net Profit Growth(56%)(50%)1005%(56%)
FCF Growth4669%(141%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Cytek Biosciences Operational KPIs

Cytek Biosciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Cytek Biosciences' Rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cytek Biosciences' Rule of X is 8% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cytek Biosciences
LTMLast FY202320242025202620272028
Rule of 404%2%
Bessemer Rule of X11%8%
Revenue per Employee$0.3M
Opex per Employee$0.2M
S&M Expenses to Revenue24%25%25%25%25%
G&A Expenses to Revenue30%29%23%22%29%
R&D Expenses to Revenue18%18%23%20%18%
Opex to Revenue72%71%66%72%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cytek Biosciences Competitors

Cytek Biosciences competitors include IBA Group, Sofwave Medical, Beta Bionics, Wellgistics Health, 2seventy bio, MiMedx Group, Cerus, AngioDynamics, The Beauty Tech Group and Tactile Medical.

Most Cytek Biosciences public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
IBA Group0.8x0.8x11.2x10.6x
Sofwave Medical5.6x64.6x
Beta Bionics3.3x2.9x(6.3x)(5.2x)
Wellgistics Health24.0x(6.0x)
2seventy bio11.2x(4.3x)
MiMedx Group1.0x1.1x3.8x5.9x
Cerus2.4x2.3x58.8x41.3x
AngioDynamics1.5x1.4x59.6x36.6x

This data is available for Pro users. Sign up to see all Cytek Biosciences competitors and their valuation data.

Start Free Trial

Cytek Biosciences Funding History

Before going public, Cytek Biosciences raised $144M in total equity funding, across 3 rounds.

Last private valuation of Cytek Biosciences was $43M, after raising $12M in January 2017 from Easy Prosperity, Eight Roads Ventures, and F-Prime.


Cytek Biosciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-20Series DHillhouse Investment; LYFE Capital; OrbiMed; RA Capital Management$120MCytek Biosciences, a Fremont, California-based provider of cell analysis instrumentation and solutions specializing in flow cytometry with compact, affordable instruments offering high multiplexing capability, closed a $120 million Series D funding round on November 6, 2020, co-led by RA Capital Management and Hillhouse Capital (also referred to as Hillhouse Investment), with participation from OrbiMed and LYFE Capital. The funding is intended to expand Cytek's global infrastructure, sustain its growing momentum, and support delivery on commitments, including branch offices and distribution channels worldwide. Cytek offers products like the Cytek Aurora and related reagents, services, and software such as SpectroFlo for researchers and clinicians in areas like immuno-oncology, infectious diseases, and drug discovery. Cytek went public via IPO in July 2021 raising $247.6 million, with total funding reaching $147.75 million across six rounds prior to IPO.
Jan-17Series BEasy Prosperity; Eight Roads Ventures; F-Prime$12M$43MCytek Biosciences raised $12M in a Series B funding round on January 25, 2017, led by Easy Prosperity with participation from Eight Roads Ventures and F-Prime. The post-money valuation for this round was $42.58M. The company develops flow cytometry instruments and reagents for biomedical research applications including immuno-oncology, infectious diseases, and inflammatory diseases. Prior to the Series B, Cytek Biosciences completed a $12.25M Series A financing round led by Easy Prosperity and F-Prime Capital. The company has raised a total of $147.75M across 6 funding rounds, culminating in an IPO raising $247.6M in July 2021.
Apr-16Series AEasy Prosperity; Eight Roads Ventures; F-Prime$12M

Cytek Biosciences M&A Activity

Cytek Biosciences has acquired 2 companies to date.

Last acquisition by Cytek Biosciences was on February 13th 2023. Cytek Biosciences acquired Flow Cytometry & Imaging for $45M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Cytek Biosciences

Flow Cytometry & Imaging
Tonbo Biosciences
Description
Flow Cytometry & Imaging is a division under DiaSorin managing Luminex technologies for flow cytometry and imaging assays. It encompasses commercial operations, R&D, and support for multiplexed analysis systems used in clinical diagnostics and research laboratories worldwide.
Tonbo Biosciences is a San Diego-based supplier of reagents for cell analysis in life sciences research. Its portfolio covers flow cytometry antibodies, cell isolation kits, PCR assays, and cell culture media targeting immunology, apoptosis, and immune profiling applications. The company distributes fluorescent dyes and viability stains compatible with major cytometers like BD FACSCalibur and Beckman Coulter models. Tonbo supports academic labs and biotech firms with bulk reagents and custom conjugations.
HQ CountryUnited StatesUnited States
HQ City
Austin, TX
San Diego, CA
Deal Date13 Feb 20233 Nov 2021
Valuation$45M$17M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cytek Biosciences acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cytek Biosciences

When was Cytek Biosciences founded?Cytek Biosciences was founded in 2014.
Where is Cytek Biosciences headquartered?Cytek Biosciences is headquartered in United States.
How many employees does Cytek Biosciences have?As of today, Cytek Biosciences has over 648 employees.
Who is the CEO of Cytek Biosciences?Cytek Biosciences' CEO is Wenbin Jiang.
Is Cytek Biosciences publicly listed?Yes, Cytek Biosciences is a public company listed on Nasdaq.
What is the stock symbol of Cytek Biosciences?Cytek Biosciences trades under CTKB ticker.
When did Cytek Biosciences go public?Cytek Biosciences went public in 2021.
Who are competitors of Cytek Biosciences?Cytek Biosciences main competitors include IBA Group, Sofwave Medical, Beta Bionics, Wellgistics Health, 2seventy bio, MiMedx Group, Cerus, AngioDynamics, The Beauty Tech Group, Tactile Medical.
What is the current market cap of Cytek Biosciences?Cytek Biosciences' current market cap is $517M.
What is the current revenue of Cytek Biosciences?Cytek Biosciences' last 12 months revenue is $204M.
What is the current revenue growth of Cytek Biosciences?Cytek Biosciences revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of Cytek Biosciences?Current revenue multiple of Cytek Biosciences is 1.4x.
Is Cytek Biosciences profitable?No, Cytek Biosciences is not profitable.
What is the current EBITDA of Cytek Biosciences?Cytek Biosciences has negative EBITDA and is not profitable.
What is Cytek Biosciences' EBITDA margin?Cytek Biosciences' last 12 months EBITDA margin is (1%).
What is the current EV/EBITDA multiple of Cytek Biosciences?Current EBITDA multiple of Cytek Biosciences is (176.7x).
How many companies Cytek Biosciences has acquired to date?As of May 2026, Cytek Biosciences has acquired 2 companies.
What was the largest acquisition by Cytek Biosciences?$45M acquisition of Flow Cytometry & Imaging on 13th February 2023 was the largest M&A Cytek Biosciences has done to date.
What companies Cytek Biosciences acquired?Cytek Biosciences acquired Flow Cytometry & Imaging and Tonbo Biosciences.
In how many companies Cytek Biosciences has invested to date?Cytek Biosciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cytek Biosciences

Lists including Cytek Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial